Play all audios:
Key themes for the day included the UK regulatory environment now and post Brexit, the accelerated access pathway for breakthrough therapies and technologies, drug device combinations and
the importance of real world evidence in regulatory decision-making.
Sir Michael Rawlins, Chairman of Medicines and Healthcare products Regulatory Agency delivered the keynote address on accelerating access to innovative therapies and implementing the AAR
recommendations under the Life Sciences Industrial Strategy.
The report brings together highlights from the day including perspectives from senior experts from across the sector including: MHRA the UK regulator, the National Institute for Biological
Standards and Control (NIBSC), the Clinical Practice Research Datalink (CPRD), the Department of Health and Social Care, the National Institute for Health and Care Excellence (NICE), the
Office for Life Sciences, notified bodies, the life science industry, research charities and patient organisations.
Chief Executive of the Medicines and Healthcare products Regulatory Agency, Dr Ian Hudson, said:
Commenting on the publication of the report, BIA CEO, Steve Bates, said:
The full report can be downloaded here and you can also find the full programme and slide presentations for this year on the conference website.